Article Text

FRI0116 Pharmacokinetic Results from a Phase 1, Single-Centre, Double-Blind, Randomised, Single-Dose, Parallel Group Study Comparing 5 MG/KG IV Infusion of BOW015 and Reference Infliximab in Healthy Male Volunteers
  1. J. Lambert1,
  2. M. Wyand2,
  3. C. Lassen2,
  4. L. Shneyer3,
  5. E. Thomson4,
  6. J. Kay5
  1. 1PAREXEL International, Harrow, United Kingdom
  2. 2Epirus Biopharmaceuticals Inc., Zug, Switzerland
  3. 3Shneyer Statistics LLC, Denville, United States
  4. 4Elizabeth Thomson Limited, Esher, United Kingdom
  5. 5UMass Memorial Medical Center and UMass Medical School, Worcester, United States


Background BOW015 is an IgG1 monoclonal antibody that binds to TNFα, which is being developed as a biosimilar to reference infliximab (rIFX, Remicade®). Preclinical studies demonstrate statistically significant dose-dependent suppression of synovitis in a murine transgenic arthritis model, with BOW015 and rIFX treatment each producing similar inhibition of joint inflammation. This clinical trial is the first-in-human study of BOW015.

Objectives To compare the pharmacokinetics (PK), safety and immunogenicity of BOW015 to rIFX in healthy Caucasian male volunteers.

Methods Eighty-four subjects were randomised to receive BOW015 or rIFX. A single 5 mg/kg IV infusion was administered over 2 hours to 43 subjects in the BOW015 group and 41 subjects in the rIFX group in a hospital-based clinical research unit. Subjects were discharged 2 days after the infusion and returned the next day for follow-up and then at 1, 2, 3, 5, 7, 9, and 12 weeks after the infusion. The treatments were compared using analysis of covariance for the PK parameters Cmax, AUC(0-t), and AUC(0-inf). The criterion for PK bioequivalence was that the 90% confidence intervals (CIs) for the geometric mean ratios were contained within the range 0.80 to 1.25.

Results Study subjects ranged in age from 18 to 45 years with body weight between 60 to 90 kg and body mass index between 19 and 27 kg/m2. Geometric mean Cmax was 142.47 μg/mL following BOW015 infusion and 126.74 μg/mL following rIFX infusion. Geometric mean AUC(0-t) was 36,211 h.μg/mL and 34,304 h.μg/mL, and geometric mean AUC(0-inf) was 36,775 and 34,801 h.μg/mL following BOW015 and rIFX infusions, respectively. Bioequivalence was demonstrated, with 90% CIs for the treatment mean ratios of 1.07 to 1.18 for Cmax, 0.98 to 1.14 for AUC(0-t), and 0.98 to 1.15 for AUC(0-inf). Apparent terminal phase half-life was similar for BOW015 (307.96 hours) and rIFX (280.22 hours). The range and median of time to peak concentration (tmax) was also similar for BOW015 (range: 2.00–8.00 hours) and rIFX (range: 2.00–12.02 hours). The median tmax for BOW015 (3.97 hours) and for rIFX (2.05 hours) was not clinically significant and may have resulted from the 2-hour interval between samples and relatively slow drug elimination. Twenty six subjects (60.5%) in the BOW015 group reported 50 treatment-emergent adverse events (TEAEs) and 27 subjects (65.9%) in the rIFX group reported 54 TEAEs. No TEAE resulted in withdrawal from the study. At Week 12, 2 subjects in the rIFX group developed a positive QuantiFERON®-TB Gold test result, both of which were reported as a TEAE. No significant differences in immunogenicity were observed between the two treatment groups, with anti-drug antibodies [ADA]) developing in 8 subjects (18.6%) in the BOW015 group and in 10 subjects (24.4%) in the rIFX group by Week 12.

Conclusions PK biosimilarity was demonstrated for BOW015 and rIFX. Both treatments were considered to be well-tolerated, with similar safety profiles and no significant difference in the proportion of subjects developing ADA. Taken in combination with efficacy data, these results establish biosimilarity between BOW015 and rIFX.

Acknowledgements This research was sponsored by EPIRUS Biopharmaceuticals Inc.

Disclosure of Interest J. Lambert: None declared, M. Wyand Employee of: Epirus Biopharmaceuticals Inc., C. Lassen Employee of: Epirus Biopharmaceuticals Inc., L. Shneyer Shareholder of: Merck, E. Thomson Consultant for: Epirus Biopharmaceuticals, J. Kay Grant/research support from: AbbVie Inc.; Eli Lilly and Company; Pfizer Inc.; Roche Laboratories, Inc. (paid to the University of Massachusetts Medical School), Consultant for: Amgen, Inc.; AbbVie Inc.; AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Epirus Biopharmaceuticals Inc.; Genentech Inc.; Hospira, Inc.; Janssen Biotech, Inc.; Merck Sharp & Dohme Corp.; Nippon Kayaku Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Samsung Bioepis; Roche Laboratories, Inc.; UCB, Inc.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.